Myomo (MYO) Short term Debt (2019 - 2025)

Myomo (MYO) posted Short term Debt of $2.7 million for Q4 2025, up 368.56% on a QoQ basis from $583333.0 in Q3 2025.

Myomo (MYO) Short term Debt (2019 - 2025) Analysis & Trends

Myomo's Short term Debt history runs 3 years deep, the most recent figure standing at $2.7 million for Q4 2025.

Quarterly Short term Debt changed N/A year-over-year to $2.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.7 million (changed N/A YoY) and the FY2025 annual result came in at $2.7 million, changed N/A from the prior year.
Short term Debt was $2.7 million for Q4 2025 at Myomo, up from $583333.0 in the prior quarter.
Across five years, Short term Debt topped out at $2.7 million in Q4 2025 and bottomed at $583333.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-
10	Myomo	39.24 Mn	20.27 Mn	-

Download Data